Axsome Therapeutics projects $638.5M revenue for 2025, driven by AUVELITY sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2025
0mins
Should l Buy AXSM?
Axsome Therapeutics (AXSM) saw its stock rise by 5.41% as it reached a 5-day high amid positive revenue projections.
The company anticipates approximately $196 million in product revenue for Q4 2025, reflecting a robust 65% year-over-year growth compared to Q4 2024. Additionally, Axsome projects total product revenue of about $638.5 million for the full year 2025, representing a 66% annual growth. This growth is driven by strong sales of AUVELITY, which is expected to reach approximately $155.1 million in Q4 2025, showcasing strong market acceptance and sales potential for this product.
These projections indicate Axsome's continued expansion in market share and profitability, likely attracting increased investor interest as the company solidifies its position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXSM
Wall Street analysts forecast AXSM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 188.690
Low
153.00
Averages
209.54
High
260.00
Current: 188.690
Low
153.00
Averages
209.54
High
260.00
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Axsome Therapeutics' Future Outlook Remains Uncertain
- Strong IPO Performance: Since its IPO in 2015, Axsome Therapeutics has achieved a compound annual growth rate of 33.32%, meaning a $50,000 investment would now be worth nearly $1 million, highlighting its robust market performance and investment appeal.
- Product Line Driving Growth: Its key product, Auvelity, saw a 66% year-over-year revenue increase in 2025, reaching $638.5 million, and is expected to expand into Alzheimer's agitation treatment, addressing the needs of over five million patients in the U.S.
- Robust Pipeline: Axsome Therapeutics has several phase 3 assets that could target over 150 million patients, with peak sales projections exceeding $16 billion for its current lineup, indicating significant future growth potential.
- Risks and Challenges: Despite strong performance, the company's long-term outlook remains uncertain, as it must navigate regulatory hurdles and market competition to ensure future clinical and commercial progress, necessitating cautious consideration from investors.
See More
Analysis of Axsome Therapeutics' Future Growth Potential
- Significant Investment Returns: Since its IPO in 2015, Axsome Therapeutics has achieved a compound annual growth rate of 33.32%, meaning a $50,000 investment would now be worth nearly $1 million, highlighting its strong market performance and investment appeal.
- Key Product Driving Growth: In 2025, Axsome's Auvelity drug saw a 66% year-over-year revenue increase to $638.5 million, with potential label expansion for agitation treatment in Alzheimer's disease, significantly broadening its market potential among over five million patients in the U.S.
- Robust Product Pipeline: Axsome boasts multiple phase 3 assets, predicting peak sales of over $16 billion for its current lineup, targeting more than 150 million patients, indicating a promising growth trajectory ahead.
- Risks and Challenges Ahead: Despite strong performance, Axsome has faced regulatory setbacks in the past, and future risks include potential market share erosion from newer drugs, necessitating careful evaluation of its long-term outlook by investors.
See More
Axsome Acquires Global Rights to TAK-063 from Takeda
- Asset Purchase Agreement: Axsome Therapeutics has signed an asset purchase agreement with Takeda Pharmaceutical to acquire exclusive global rights to TAK-063 (balipodect), further expanding its leading CNS portfolio and demonstrating strategic positioning in neuropsychiatric treatment.
- Clinical Trial Plans: Axsome intends to initiate Phase 3 trial-enabling activities for schizophrenia in 2026, indicating strong confidence in the development of balipodect and aiming to improve treatment outcomes for patients through this novel mechanism.
- Clinical Trial Results: Balipodect has shown positive results in a 164-patient proof-of-concept Phase 2 trial for schizophrenia and has demonstrated a favorable safety and tolerability profile in clinical studies involving over 360 individuals, enhancing its market potential.
- Financial Arrangement: Under the agreement, Axsome obtains worldwide commercial, development, and manufacturing rights to balipodect, while Takeda receives an upfront payment and is eligible for additional payments related to development, regulatory, and commercial milestones, as well as royalties on potential global net sales, ensuring mutual benefit.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
See More
Summit Therapeutics Faces FDA Approval Risk for Ivonescimab
- FDA Approval Crucial: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, the drug has not shown statistically significant overall survival in Western countries, and a rejection could lead to a significant drop in stock price.
- Intensifying Market Competition: Axsome Therapeutics and Madrigal Pharmaceuticals have market caps of $8.1 billion and $10.2 billion respectively, with both companies poised to potentially surpass Summit by 2026, highlighting the fierce competition in the biotech sector.
- Axsome's Growth Momentum: Axsome Therapeutics reported a 65.5% revenue increase in 2025, reaching $638.5 million, and is awaiting FDA approval for its Alzheimer's drug AXS-05, which could significantly expand its market reach.
- Madrigal's Sales Surge: Madrigal Pharmaceuticals achieved $958.4 million in sales from its Rezdiffra drug in 2025, a 432% increase from 2024, indicating strong growth potential in the metabolic dysfunction space, with expectations for continued excellent financial performance.
See More
Axsome Therapeutics' Future Outlook Remains Uncertain
- Strong IPO Performance: Since its IPO in 2015, Axsome Therapeutics has achieved a compound annual growth rate of 33.32%, meaning a $50,000 investment would now be worth nearly $1 million, highlighting its robust market performance and investment appeal.
- Product Line Driving Growth: Its key product, Auvelity, saw a 66% year-over-year revenue increase in 2025, reaching $638.5 million, and is expected to expand into Alzheimer's agitation treatment, addressing the needs of over five million patients in the U.S.
- Robust Pipeline: Axsome Therapeutics has several phase 3 assets that could target over 150 million patients, with peak sales projections exceeding $16 billion for its current lineup, indicating significant future growth potential.
- Risks and Challenges: Despite strong performance, the company's long-term outlook remains uncertain, as it must navigate regulatory hurdles and market competition to ensure future clinical and commercial progress, necessitating cautious consideration from investors.
See More
Analysis of Axsome Therapeutics' Future Growth Potential
- Significant Investment Returns: Since its IPO in 2015, Axsome Therapeutics has achieved a compound annual growth rate of 33.32%, meaning a $50,000 investment would now be worth nearly $1 million, highlighting its strong market performance and investment appeal.
- Key Product Driving Growth: In 2025, Axsome's Auvelity drug saw a 66% year-over-year revenue increase to $638.5 million, with potential label expansion for agitation treatment in Alzheimer's disease, significantly broadening its market potential among over five million patients in the U.S.
- Robust Product Pipeline: Axsome boasts multiple phase 3 assets, predicting peak sales of over $16 billion for its current lineup, targeting more than 150 million patients, indicating a promising growth trajectory ahead.
- Risks and Challenges Ahead: Despite strong performance, Axsome has faced regulatory setbacks in the past, and future risks include potential market share erosion from newer drugs, necessitating careful evaluation of its long-term outlook by investors.
See More
Axsome Acquires Global Rights to TAK-063 from Takeda
- Asset Purchase Agreement: Axsome Therapeutics has signed an asset purchase agreement with Takeda Pharmaceutical to acquire exclusive global rights to TAK-063 (balipodect), further expanding its leading CNS portfolio and demonstrating strategic positioning in neuropsychiatric treatment.
- Clinical Trial Plans: Axsome intends to initiate Phase 3 trial-enabling activities for schizophrenia in 2026, indicating strong confidence in the development of balipodect and aiming to improve treatment outcomes for patients through this novel mechanism.
- Clinical Trial Results: Balipodect has shown positive results in a 164-patient proof-of-concept Phase 2 trial for schizophrenia and has demonstrated a favorable safety and tolerability profile in clinical studies involving over 360 individuals, enhancing its market potential.
- Financial Arrangement: Under the agreement, Axsome obtains worldwide commercial, development, and manufacturing rights to balipodect, while Takeda receives an upfront payment and is eligible for additional payments related to development, regulatory, and commercial milestones, as well as royalties on potential global net sales, ensuring mutual benefit.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
See More
Summit Therapeutics Faces FDA Approval Risk for Ivonescimab
- FDA Approval Crucial: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, the drug has not shown statistically significant overall survival in Western countries, and a rejection could lead to a significant drop in stock price.
- Intensifying Market Competition: Axsome Therapeutics and Madrigal Pharmaceuticals have market caps of $8.1 billion and $10.2 billion respectively, with both companies poised to potentially surpass Summit by 2026, highlighting the fierce competition in the biotech sector.
- Axsome's Growth Momentum: Axsome Therapeutics reported a 65.5% revenue increase in 2025, reaching $638.5 million, and is awaiting FDA approval for its Alzheimer's drug AXS-05, which could significantly expand its market reach.
- Madrigal's Sales Surge: Madrigal Pharmaceuticals achieved $958.4 million in sales from its Rezdiffra drug in 2025, a 432% increase from 2024, indicating strong growth potential in the metabolic dysfunction space, with expectations for continued excellent financial performance.
See More
